PMID- 30116491
OWN - NLM
STAT- MEDLINE
DCOM- 20181219
LR  - 20181219
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2018
DP  - 2018
TI  - Solid Lipid Nanoparticles of Myricitrin Have Antioxidant and Antidiabetic Effects 
      on Streptozotocin-Nicotinamide-Induced Diabetic Model and Myotube Cell of Male 
      Mouse.
PG  - 7496936
LID - 10.1155/2018/7496936 [doi]
LID - 7496936
AB  - Type 2 diabetes mellitus (T2DM) may occur via oxidative stress. Myricitrin is a 
      plant-derived antioxidant, and its solid lipid nanoparticle (SLN) may be more 
      potent. Hence, the present study was conducted to evaluate the effects of 
      myricitrin SLN on streptozotocin-nicotinamide- (STZ-NA-) induced T2DM of the 
      mouse and hyperglycemic myotube. In this experimental study, cold homogenization 
      method was used to prepare SLN. Then, 120 adult male NMRI mice were divided into 
      7 groups: control, vehicle, diabetes (received STZ 65 mg/kg 15 min after injected 
      NA 120 mg/kg), diabetes + SLN containing myricitrin 1, 3, and 10 mg/kg, and 
      diabetes + metformin. For in vitro study, myoblast (C2C12) cell line was cultured 
      and divided into 6 groups (n = 3): control, hyperglycemia, hyperglycemia + SLN 
      containing myricitrin 1, 3, and, 10 muM, and hyperglycemia + metformin. After the 
      last nanoparticle treatment, plasma samples, pancreas and muscle tissues, and 
      myotubes were taken for experimental assessments. Diabetes increased lipid 
      peroxidation and reduced antioxidant defense along with the hyperglycemia, 
      insulin resistance, and pancreas apoptosis. Hyperglycemia induced oxidative 
      stress, antioxidant impairment, and cellular apoptosis. Myricitrin SLN improved 
      diabetes and hyperglycemia complications in the in vivo and in vitro studies. 
      Therefore, SLN of myricitrin showed antioxidant, antidiabetic, and antiapoptotic 
      effects in the mouse and myotube cells.
FAU - Ahangarpour, Akram
AU  - Ahangarpour A
AD  - Department of Physiology, Faculty of Medicine, Diabetes Research Center, Health 
      Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, 
      Iran.
FAU - Oroojan, Ali Akbar
AU  - Oroojan AA
AUID- ORCID: 0000-0001-5249-3239
AD  - Department of Physiology, Faculty of Medicine, Cellular and Molecular Research 
      Center, Student Research Committee, Ahvaz Jundishapur University of Medical 
      Sciences, Ahvaz, Iran.
FAU - Khorsandi, Layasadat
AU  - Khorsandi L
AD  - Department of Anatomical Sciences, Faculty of Medicine, Cellular and Molecular 
      Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Kouchak, Maryam
AU  - Kouchak M
AD  - Department of Pharmaceutical Sciences, Faculty of Pharmacy, Nanotechnology 
      Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
FAU - Badavi, Mohammad
AU  - Badavi M
AD  - Department of Physiology, Faculty of Medicine, Physiology Research Center, Ahvaz 
      Jundishapur University of Medical Sciences, Ahvaz, Iran.
LA  - eng
PT  - Journal Article
DEP - 20180717
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (Antioxidants)
RN  - 0 (Flavonoids)
RN  - 0 (Hypoglycemic Agents)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 5W494URQ81 (Streptozocin)
RN  - 5Z0ZO61WPJ (myricitrin)
SB  - IM
MH  - Animals
MH  - Antioxidants/pharmacology/*therapeutic use
MH  - Disease Models, Animal
MH  - Flavonoids/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Male
MH  - Mice
MH  - Middle Aged
MH  - Muscle Fibers, Skeletal/*metabolism
MH  - Nanoparticles/*chemistry
MH  - Niacinamide/*adverse effects
MH  - Streptozocin/*adverse effects
PMC - PMC6079346
EDAT- 2018/08/18 06:00
MHDA- 2018/12/20 06:00
PMCR- 2018/07/17
CRDT- 2018/08/18 06:00
PHST- 2018/02/17 00:00 [received]
PHST- 2018/05/12 00:00 [revised]
PHST- 2018/05/31 00:00 [accepted]
PHST- 2018/08/18 06:00 [entrez]
PHST- 2018/08/18 06:00 [pubmed]
PHST- 2018/12/20 06:00 [medline]
PHST- 2018/07/17 00:00 [pmc-release]
AID - 10.1155/2018/7496936 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2018 Jul 17;2018:7496936. doi: 10.1155/2018/7496936. 
      eCollection 2018.